A clinician on the other end of every dose.
Compounded semaglutide injection with clinician review, pharmacy fulfillment, shipping, and follow-up inside one care model.
Compounded semaglutide and tirzepatide are not FDA-approved products. They are prescribed by licensed clinicians based on individual clinical evaluation and prepared by a licensed 503A pharmacy. Not all patients qualify.
About 10 minutes. No charge unless your clinician approves.
Work on the signal, not the self-criticism.
There is a limit to how useful “try harder” becomes when appetite is doing something different from the plan you wrote on Sunday. Hunger, satiety, gastric emptying, and glucose regulation are biological systems, not character traits.
Semaglutide works inside that biology.
It is a GLP-1 receptor agonist, a synthetic analog of a hormone involved in post-meal signaling. GLP-1 receptor activity affects appetite signaling, gastric emptying, and glucose-dependent insulin response. That gives the medication a defined physiological target instead of asking behavior to carry the entire metabolic burden alone.
The compounded prescription is clinician-directed from the beginning. Your provider reviews candidacy, health history, medications, side-effect risk, and the larger metabolic plan before prescribing, then adjusts treatment from your response and tolerability rather than asking you to follow a dosing schedule from the internet.
The evidence stays attached to the products and formulations that produced it, while your own plan remains clinician-directed.
Read the evidence →For people tired of treating appetite like a moral failing.
The Willpower Skeptic
You can follow a plan and still find that hunger keeps renegotiating it. You want a clinician to evaluate whether appetite signaling deserves a medical intervention rather than another lecture about discipline.
The Plateau Patient
Training and nutrition are still present, but progress has stopped matching the effort. You want the metabolic picture reviewed before the answer becomes simply more restriction.
The Restart With History
You have lost weight before and watched the old pattern return. This time you want pharmacology, nutrition, side-effect management, and follow-up to live inside one plan rather than another isolated attempt.
Compounded semaglutide is not an FDA-approved drug product. Candidacy, dose, and whether it belongs alongside anything else you take are determined by a licensed provider from your full intake.
This might not be the right fit if:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy or planned pregnancy
- Type 1 diabetes or insulin-dependent regimens without specialist oversight
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Semaglutide, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- GLP-1 receptor agonism addressing appetite and glucose signaling
- Provider-directed treatment adjustments based on response and tolerability
- Supportive care considered where clinically appropriate
- Ongoing provider review and messaging access through the care plan
- Prepared to your individual prescription by a licensed 503A pharmacy
Compounded semaglutide and tirzepatide are not FDA-approved products. They are prescribed by licensed clinicians based on individual clinical evaluation and prepared by a licensed 503A pharmacy. Not all patients qualify.
More in Metabolic.
Tirzepatide
Two incretin pathways. One physician watching both.
Compounded tirzepatide injection built around dual GIP and GLP-1 receptor biology with clinician-directed dosing and follow-up. (Contains tirzepatide.)
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
Tirzepatide + B12 Microdose
Dual-pathway biology at a lower starting scale.
A lower-dose compounded tirzepatide and B12 prescription that keeps dual-receptor biology inside clinician-led care. (Contains tirzepatide and vitamin B12.)
What the research shows
GLP-1 is a gut hormone released at meals and inactivated extremely rapidly.
The detail
Glucagon-like peptide-1 is a 30-amino-acid peptide hormone produced in intestinal epithelial endocrine L-cells by differential processing of proglucagon, released in response to meal intake, and inactivated extremely rapidly by the enzyme dipeptidyl peptidase-4.1
GLP-1 drives glucose-dependent insulin release, slows gastric emptying and promotes satiety.
The detail
As an incretin it is secreted within minutes of nutrient ingestion, and incretin-receptor activation on pancreatic islet beta-cells leads to glucose-dependent insulin secretion, while glucagon-like peptide-1 additionally exerts glucoregulatory action through slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion and promotes satiety.2
Semaglutide is a GLP-1 analogue that binds the same receptor as the native hormone.
The detail
Semaglutide is a GLP-1 analogue with 94 percent sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor, the target for the native hormone, and FDA labeling describes the resulting glucose-lowering mechanism as stimulation of insulin secretion and lowering of glucagon secretion, both in a glucose-dependent manner, together with a minor delay in gastric emptying in the early postprandial phase.3
Labeling calls GLP-1 an appetite regulator; the brain findings for semaglutide are from animals.
The detail
FDA labeling further describes glucagon-like peptide-1 as a physiological regulator of appetite and caloric intake, states that the GLP-1 receptor is present in several areas of the brain involved in appetite regulation, and reports that animal studies show semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake.4
Albumin binding gives semaglutide a half-life of about one week, hence weekly dosing.
The detail
The pharmacokinetic basis for once-weekly subcutaneous administration is described in the same labeling as albumin binding, identified as the principal mechanism of protraction because it decreases renal clearance and protects against metabolic degradation, with semaglutide extensively bound to plasma albumin at greater than 99 percent, an elimination half-life of approximately one week, and steady-state exposure reached after four to five weekly doses.5
What it does not show
A compounded preparation is not an FDA-approved drug product.
The detail
A compounded preparation is not an FDA-approved drug product: FDA states that compounded drugs are not FDA-approved and that the agency does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.6
Everything here is mechanism from labeling, not trial results.
The detail
Everything above is drawn from the clinical pharmacology section of FDA labeling, which describes how the molecule acts. This block deliberately stops there rather than reproducing the separate clinical studies section in which trial results for FDA-approved finished drug products are reported, because a described pathway is not a measured outcome.3
The pharmacokinetic numbers describe the approved product, not a compounded preparation.
The brain findings are rodent data, not a measured human response.
The detail
The central nervous system statements above are characterized in labeling as animal findings, and animal data on distribution to brain regions and activation of neurons describe rodent physiology rather than a measured human response.4
FDA calls it a warning sign to claim a compounded drug equals an approved one.
The detail
FDA advises that compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug, and identifies a claim that a compounded drug is the same as an FDA-approved drug as a warning sign for consumers.7
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
- FDA-approved semaglutide injection prescribing information, section…DailyMed
- FDA-approved semaglutide prescribing information, section 12.1…DailyMed
- FDA-approved semaglutide injection prescribing information, section…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.FDA
FDA-approved semaglutide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
Serious risks
- Pancreatitis
- Gallbladder disease
- Acute kidney injury following the fluid loss that severe vomiting or diarrhea can cause
Commonly reported
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
What most people report is gastrointestinal, most often while the dose is being adjusted. The serious risks are in semaglutide labeling. That warning is why your provider also reviews pancreatitis history, pregnancy plans, and any medication you take that lowers blood sugar. This preparation is compounded rather than an FDA-approved finished drug product, so it has no safety database of its own and your clinician reasons from the labeled risks of the approved products. Those judgments belong to the prescribing clinician, which is the reason this sits with a provider rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
It contains the same active molecule, semaglutide, prepared by a licensed compounding pharmacy. Compounded medications are not FDA-approved products; they are prescribed when a licensed clinician determines they are appropriate for you.
Your clinician directs the treatment schedule and any adjustments based on your response and tolerability. You do not determine or change the dose on your own.
Common side effects include nausea, vomiting, diarrhea, abdominal pain, constipation, and reflux. Semaglutide also carries important risks including pancreatitis, gallbladder disease, acute kidney injury associated with volume depletion, severe gastrointestinal reactions, and other serious adverse effects. FDA-approved semaglutide products used for chronic weight management carry a boxed warning concerning thyroid C-cell tumors observed in rodents. Your clinician reviews those risks and your medical history before prescribing and can adjust treatment or consider supportive medication where clinically appropriate.
Your provider determines whether labs are needed based on your Assessment and history.